Probiotic

Probiotics are live microorganisms thought to be healthy for the host organism. According to the currently adopted definition by FAO/WHO, probiotics are: "Live microorganisms which when administered in adequate amounts confer a health benefit on the host".[1] Lactic acid bacteria (LAB) and bifidobacteria are the most common types of microbes used as probiotics; but certain yeasts and bacilli may also be helpful. Probiotics are commonly consumed as part of fermented foods with specially added active live cultures; such as in yogurt, soy yogurt, or as dietary supplements.

Etymologically, the term appears to be a composite of the Latin preposition pro ("for") and the Greek adjective βιωτικός (biotic), the latter deriving from the noun βίος (bios, "life").[2]
At the start of the 20th century, probiotics were thought to beneficially affect the host by improving its intestinal microbial balance, thus inhibiting pathogens and toxin producing bacteria.[3] Today, specific health effects are being investigated and documented including alleviation of chronic intestinal inflammatory diseases,[4] prevention and treatment of pathogen-induced diarrhea,[5] urogenital infections,[6] and atopic diseases.[7]

Contents

History of probiotics

The original observation of the positive role played by certain bacteria was first introduced by Russian scientist and Nobel laureate Eli Metchnikoff, who in the beginning of the 20th century suggested that it would be possible to modify the gut flora and to replace harmful microbes by useful microbes.[3] Metchnikoff, at that time a professor at the Pasteur Institute in Paris, produced the notion that the aging process results from the activity of putrefactive (proteolytic) microbes producing toxic substances in the large bowel. Proteolytic bacteria such as clostridia, which are part of the normal gut flora, produce toxic substances including phenols, indols and ammonia from the digestion of proteins. According to Metchnikoff these compounds were responsible for what he called "intestinal auto-intoxication", which caused the physical changes associated with old age.

It was at that time known that milk fermented with lactic-acid bacteria inhibits the growth of proteolytic bacteria because of the low pH produced by the fermentation of lactose. Metchnikoff had also observed that certain rural populations in Europe, for example in Bulgaria and the Russian steppes who lived largely on milk fermented by lactic-acid bacteria were exceptionally long lived. Based on these facts, Metchnikoff proposed that consumption of fermented milk would "seed" the intestine with harmless lactic-acid bacteria and decrease the intestinal pH and that this would suppress the growth of proteolytic bacteria. Metchnikoff himself introduced in his diet sour milk fermented with the bacteria he called "Bulgarian Bacillus" and found his health benefited. Friends in Paris soon followed his example and physicians began prescribing the sour milk diet for their patients.[8]

Bifidobacteria were first isolated from a breast-fed infant by Henry Tissier who also worked at the Pasteur Institute. The isolated bacterium named Bacillus bifidus communis[9] was later renamed to the genus Bifidobacterium. Tissier found that bifidobacteria are dominant in the gut flora of breast-fed babies and he observed clinical benefits from treating diarrhea in infants with bifidobacteria. The claimed effect was bifidobacterial displacement of proteolytic bacteria causing the disease.

During an outbreak of shigellosis in 1917, German professor Alfred Nissle isolated a strain of Escherichia coli from the feces of a soldier who was not affected by the disease.[10] Methods of treating infectious diseases were needed at that time when antibiotics were not yet available, and Nissle used the Escherichia coli Nissle 1917 strain in acute gastrointestinal infectious salmonellosis and shigellosis.

In 1920, Rettger demonstrated that Metchnikoff's "Bulgarian Bacillus", later called Lactobacillus delbrueckii subsp. bulgaricus, could not live in the human intestine,[11] and the fermented food phenomena petered out. Metchnikoff's theory was disputable (at this stage), and people doubted his theory of longevity.

After Metchnikoff's death in 1916, the centre of activity moved to the United States. It was reasoned that bacteria originating from the gut were more likely to produce the desired effect in the gut, and in 1935 certain strains of Lactobacillus acidophilus were found to be very active when implanted in the human digestive tract.[12] Trials were carried out using this organism, and encouraging results were obtained especially in the relief of chronic constipation.

The term "probiotics" was first introduced in 1953 by Kollath (see Hamilton-Miller et al. 2003). Contrasting antibiotics, probiotics were defined as microbially derived factors that stimulate the growth of other microorganisms. In 1989 Roy Fuller suggested a definition of probiotics which has been widely used: "A live microbial feed supplement which beneficially affects the host animal by improving its intestinal microbial balance".[13] Fuller's definition emphasizes the requirement of viability for probiotics and introduces the aspect of a beneficial effect on the host.

In the following decades intestinal lactic acid bacterial species with alleged health beneficial properties have been introduced as probiotics, including Lactobacillus rhamnosus, Lactobacillus casei, and Lactobacillus johnsonii.[14]

Potential benefits

Experiments into the benefits of probiotic therapies suggest a range of potentially beneficial medicinal uses for probiotics. For many of the potential benefits, research is limited and only preliminary results are available. It should be noted that the effects described are not general effects of probiotics. Recent research on the molecular biology and genomics of Lactobacillus has focused on the interaction with the immune system, anti-cancer potential, and potential as a biotherapeutic agent in cases of antibiotic-associated diarrhoea, travellers' diarrhoea, pediatric diarrhoea, inflammatory bowel disease and irritable bowel syndrome.[15]

All effects can only be attributed to the individual strain(s) tested. Testing of a supplement does not indicate benefit from any other strain of the same species, and testing does not indicate benefit from the whole group of LAB (or other probiotics).[16]

Managing lactose intolerance

As lactic acid bacteria actively convert lactose into lactic acid, ingestion of certain active strains may help lactose intolerant individuals tolerate more lactose than what they would have otherwise.[17]

Prevention of colon cancer

In laboratory investigations, some strains of LAB (Lactobacillus bulgaricus) have demonstrated anti-mutagenic effects thought to be due to their ability to bind with heterocyclic amines, which are carcinogenic substances formed in cooked meat.[18] Animal studies have demonstrated that some LAB can protect against colon cancer in rodents, though human data is limited and conflicting.[19] Most human trials have found that the strains tested may exert anti-carcinogenic effects by decreasing the activity of an enzyme called β-glucuronidase[19] (which can generate carcinogens in the digestive system). Lower rates of colon cancer among higher consumers of fermented dairy products have been observed in one population study.[17]

Lowering cholesterol

Animal studies have demonstrated the efficacy of a range of LAB to be able to lower serum cholesterol levels, presumably by breaking down bile in the gut, thus inhibiting its reabsorption (which enters the blood as cholesterol). Some, but not all human trials have shown that dairy foods fermented with specific LAB can produce modest reductions in total and LDL cholesterol levels in those with normal levels to begin with, however trials in hyperlipidemic subjects are needed.[17]

Lowering blood pressure

Several small clinical trials have indicated that consumption of milk fermented with various strains of LAB may result in modest reductions in blood pressure. It is thought that this is due to the ACE inhibitor-like peptides produced during fermentation.[17]

Improving immune function and preventing infections

LAB are thought to have several presumably beneficial effects on immune function. They may protect against pathogens by means of competitive inhibition (i.e., by competing for growth) and there is evidence to suggest that they may improve immune function by increasing the number of IgA-producing plasma cells, increasing or improving phagocytosis as well as increasing the proportion of T lymphocytes and Natural Killer cells.[20][21] Clinical trials have demonstrated that probiotics may decrease the incidence of respiratory tract infections[22] and dental caries in children.[23] LAB foods and supplements have been shown to aid in the treatment and prevention of acute diarrhea, and in decreasing the severity and duration of rotavirus infections in children and travelers' diarrhea in adults.[20][21]

A 2010 study suggested that the anecdotal benefits of probiotic therapies as beneficial for preventing secondary infections, a common complication of antibiotic therapy, may be because keeping the immune system primed by eating foods enhanced with "good" bacteria may help counteract the negative effects of sickness and antibiotics. It was thought that antibiotics may turn the immune system "off" while probiotics turns it back on "idle", and more able to quickly react to new infections.[24]

Helicobacter pylori

LAB are also thought to aid in the treatment of Helicobacter pylori infections (which cause peptic ulcers) in adults when used in combination with standard medical treatments. However more studies are required into this area.[25]

Antibiotic-associated diarrhea

Antibiotic-associated diarrhea (AAD) results from an imbalance in the colonic microbiota caused by antibiotic therapy. Microbiota alteration changes carbohydrate metabolism with decreased short-chain fatty acid absorption and an osmotic diarrhea as a result. Another consequence of antibiotic therapy leading to diarrhea is overgrowth of potentially pathogenic organisms such as Clostridium difficile.

Probiotic treatment can reduce the incidence and severity of AAD as indicated in several meta-analyses.[26][27][28][29][30][31] However, further documentation of these findings through randomized, double blind, placebo-controlled trials are warranted.

Efficacy of probiotic AAD prevention is dependent on the probiotic strain(s) used and on the dosage.[32][33] Up to a 50% reduction of AAD occurrence has been found.[31] No side-effects have been reported in any of these studies. Caution should, however, be exercised when administering probiotic supplements to immunocompromised individuals or patients who have a compromised intestinal barrier.

Reducing inflammation

LAB and supplements have been found to modulate inflammatory and hypersensitivity responses, an observation thought to be at least in part due to the regulation of cytokine function.[20] Clinical studies suggest that they can prevent reoccurrences of inflammatory bowel disease in adults,[20] as well as improve milk allergies.[34] They are not effective for treating eczema, a persistent skin inflammation.[35] How probiotics counteract immune system overactivity remains unclear, but a potential mechanism is desensitization of T lymphocytes, an important component of the immune system, towards pro-inflammatory stimuli .[36]

Improving mineral absorption

It is hypothesized that probiotic lactobacilli may help correct malabsorption of trace minerals, found particularly in those with diets high in phytate content from whole grains, nuts, and legumes.[37]

Preventing harmful bacterial growth under stress

In a study done to see the effects of stress on intestinal flora, rats that were fed probiotics had little occurrence of harmful bacteria latched onto their intestines compared to rats that were fed sterile water.[38]

Irritable bowel syndrome and colitis

B. infantis 35624, sold as Align, was found to improve some symptoms of irritable bowel syndrome in women in a recent study.[39] Another probiotic bacterium, Lactobacillus plantarum 299v, was also found to be effective in reducing IBS symptoms.[40] Additionally, a probiotic formulation, VSL#3, was found to be safe in treating ulcerative colitis, though efficacy in the study was uncertain.[41] Bifidobacterium animalis DN-173 010 may help.[42] For maintenance of remission of ulcerative colitis, Mutaflor (E.coli Nissle 1917) there are 3 controlled, randomized, double blind clinical studies which have proven equivalence of Mutaflor and mesalazine (5-ASAs).[43]

Managing urogenital health

Several in vitro studies have revealed probiotics' potential in relieving urinary tract infections[44] and bacterial vaginosis.[45] Results have been varied on these studies, and in vivo studies are still required in this area to determine efficacy.

Disadvantages of probiotics

In some specific situations (such as critically ill patients) they could be harmful. In a therapeutic clinical trial conducted by the Dutch Pancreatitis Study Group, the consumption of a mixture of six probiotic bacteria, increased the death rate of patients with predicted severe acute pancreatitis.[46]

In a clinical trial conducted at the University of Western Australia, aimed at showing the effectiveness of probiotics in reducing childhood allergies, Dr Susan Prescott and her colleagues gave 178 children either a probiotic or a placebo for the first six months of their life. Those given the good bacteria were more likely to develop a sensitivity to allergens.[47]

Some hospitals have reported treating lactobacillus septicaemia, which is a potentially fatal disease caused by the consumption of probiotics by people with lowered immune systems or who are already very ill.[47][48]

There is no published evidence that probiotic supplements are able to replace the body's natural flora when these have been killed off; indeed bacterial levels in feces disappear within days when supplementation ceases.[49]

Recent studies indicate that probiotic products such as yogurts could be a cause for obesity trends.[50] However, this is contested.[51][52]

Strains

Live probiotic cultures are available in fermented dairy products and probiotic fortified foods. However, tablets, capsules, powders and sachets containing the bacteria in freeze dried form are also available.

Probiotic Research and Producer Information[53]
Strain Brandname Producer Potential effect in humans
Bacillus coagulans GBI-30, 6086 GanedenBC30 Ganeden Biotech Improves abdominal pain and bloating in IBS patients.[54] Increases immune response to viral challenge.[55]
Bifidobacterium LAFTI® B94 Bifidobacterium sp LAFTI B94 Institut Rosell-Lallemand Protects against Salmonella typhimurium in mice18,20

Utilises prebiotics for improved colonisation20,21 Facilitates apoptotic response when used in combination with resistant starch in a colon cancer model19 Reduces inflammation and incidence of diarrhoea in an IBD model22 Reduces allergic responses in an allergy model23 Reduces the severity of H.pylori infection of the stomach mucosa24 Inhibits pathogenic bacteria (H. pylori7; List monocytogenes; E. coli8,13,16; Salmonella typhimurium16,18 ) Survives in the conditions of the gastro-intestinal tract5 Adheres to human intestinal cells4 Utilises prebiotics5,6 Synthesises and utilizes folate in yoghurt25|-

Lactobacillus acidophilus LAFTI® L10 Lactobacillus acidophilus LAFTI L10 Institut Rosell-Lallemand Enhances clearance of Candida albicans by induction of

an immune response9 Reduces allergic responses in an allergy model11,23 Protects against Listeria monocytogenes in the gastro- intestinal tract of mice8 Reduces the incidence of tumour formation and the size of intestinal tumors in rats14 Utilises prebiotics for improved colonisation21 Reduces inflammation in an IBD model22 Inhibits pathogenic bacteria (H. pylori 7; List. monocytogenes; E. coli 8,13,16; Salmonella typhimurium16) Superior survival in the conditions of the gastro-intestinal tract compared to other probiotics1,2 Adheres to human intestinal cells4 Produces anti-microbial substances like H202 Utilises prebiotics6|-

Lactobacillus casei LAFTI® L26 Lactobacillus casei LAFTI L26 Institut Rosell-Lallemand Protects against Salmonella typhimurium in mice12, 20

Utilises prebiotics for improved colonisation20,21 Reduces inflammation in an IBD model22 Reduces allergic responses in an allergy model23 Reduces the severity of H.pylori infection of the stomach mucosa24 Inhibits pathogenic bacteria (H. pylori7; List. monocytogenes; E. coli8,13,16; Salmonella typhimurium16,20) Survives in the conditions of the gastro-intestinal tract12 Adheres to human intestinal cells4 Utilises prebiotics6|-

Bifidobacterium animalis subsp. lactis BB-12 Probio-Tec® Bifidobacterium BB-12® Chr. Hansen Alleviates symptoms of atopic eczema

Has an immune modulating effect

Bifidobacterium breve Yakult Bifiene Yakult
Bifidobacterium infantis 35624 Align Procter & Gamble Showed significant improvement for abdominal pain/discomfort, bloating/distention, and/or bowel movement difficulty.[56]
Bifidobacterium animalis subsp. lactis HN019 (DR10) Howaru Bifido Danisco
Bifidobacterium longum BB536 Morinaga Milk Industry
Escherichia coli M-17 ProBactrix BioBalance
Escherichia coli Nissle 1917 Mutaflor Ardeypharm
Lactobacillus acidophilus DDS-1 Nebraska Cultures[57]
Lactobacillus acidophilus LA-5 Chr. Hansen
Lactobacillus acidophilus NCFM Danisco
Lactobacillus casei DN114-001 (Lactobacillus casei Immunitas(s)/Defensis) Actimel/DanActive Danone
Lactobacillus casei 431 Chr. Hansen
Lactobacillus casei F19 Cultura Arla Foods
Lactobacillus casei Shirota Yakult Yakult
Lactobacillus paracasei St11 (or NCC2461)[58] Lactobacillus fortis Nestlé
Lactobacillus johnsonii La1 (= Lactobacillus LC1, Lactobacillus johnsonii NCC533) Nestlé
Lactococcus lactis L1A Norrmejerier Immune stimulation, improves digestive health, reduces antibiotic-associated diarrhoea[59]
Lactobacillus plantarum 299v GoodBelly / ProViva/ TuZen Probi
Lactobacillus reuteri ATTC 55730 (Lactobacillus reuteri SD2112) BioGaia Biologics Diarrhea prevention and mitigation in children,[60][61] eradication of H. pylori infection,[62] amelioration of gingivitis,[63] general illness prevention in children[64] and adults.[65]
Lactobacillus rhamnosus ATCC 53013 (Also strain number GG, discovered by Gorbach & Goldin) LGG, Vifit and others Valio
Lactobacillus rhamnosus LB21 Verum Norrmejerier Immune stimulation, improves digestive health, reduces antibiotic-associated diarrhoea[59]
Saccharomyces cerevisiae (boulardii) lyo DiarSafe and others Wren Laboratories and others against antibiotic-associated diarrhoea and Clostridium difficile infections; to treat acute diarrhoea in adults & children...[66][67][68]
tested as mixture:
Lactobacillus rhamnosus GR-1 & Lactobacillus reuteri RC-14
Bion Flore Intime Jarrow Fem-Dophilus Chr. Hansen Oral ingestion results in vaginal colonisation and prevention of vaginitis

[69]

tested as mixture:
Lactobacillus acidophilus NCFM & Bifidobacterium bifidum BB-12
Florajen3 American Lifeline, Inc Reduction of C. difficile–associated disease (CDAD)[2].
tested as mixture:
Lactobacillus acidophilus CL1285 & Lactobacillus casei
Bio-K+ CL1285 Bio-K+ International Improves digestive health. Prevents Antiobic Associated Diarrhea (AAD) and Clostridium Difficile (C Difficile).[70]

In vitro inhibition of Listeria monocytogenes and L. innocua, Escherichia coli, Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.[71]
Reduction of symptoms of lactose intolerance and immune stimulation.[72]

Lactobacillus helveticus R0052 & Lactobacillus rhamnosus R0011 A'Biotica and others Institut Rosell

Some other bacteria mentioned in probiotic products: (yoghurt bacteria):

Some fermented products containing similar lactic acid bacteria include:

Multi-probiotic

Research is emerging on the potential health benefits of multiple probiotic strains as a health supplement as opposed to a single strain.[80][81] The human gut is home to some 400-500 types of microbes. It is thought that this diverse environment may benefit from multiple probiotic strains; different strains populate different areas of the digestive tract, and studies are beginning to link different probiotic strains to specific health benefits.

Supplement products that contain more than one probiotic strain:

Company Product Probiotic Strains Strain Qty
EMD Canada Inc. Multibionta Lactobacillus gasseri PA16/8, Bifidobacterium bifidum MF20/5, Bifidobacterium longum SP07/3 3
Enzymatic Therapy Acidophilus Pearls Lactobacillus acidophilus, Bifidobacterium longum 2
Kyolic Kyo-Dophilus Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium longum 3
New Chapter Probiotic Colon Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium breve, Streptococcus thermophilus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus salivarius, Lactobacillus acidophilus, Lactobacillus rhamnosus 10
OptiBac Probiotics For daily wellbeing Bifidobacterium longum Rosell-175, Lactococcus lactis Rosell-1058, Bifidobacterium breve Rosell-70, Lactobacillus rhamnosus Rosell-11, Lactobacillus acidophilus Rosell-52, Bifidobacterium bifidum rosell-71 6
Renew Life Flora Smart Bifidobacterium bifidum, Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus casei, Lactobacillus plantarum, Lactococcus lactis, Lactobacillus bulgaricus, Lactobacillus salivarius 10
Sedona Labs iFlora Multi-Probiotic Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactococcus lactis, Streptococcus thermophilus 16
SCD Probiotics Essential Probiotics Bacillus subtilis var natto, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus delbrueckii, Lactobacillus fermentum, Lactobacillus plantarum, Lactococcus lactis, Lactococcus lactis subsp. Diacetylactis, Saccharomyces cerevisiae, Streptococcus thermophilus 14
Symprove Ltd Symprove live activated probiotic Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus Casei, var. Rhamnosus, Enterococcus faecium, all in active state not freeze-dried 4

Synbiotics and Prebiotics

While related, prebiotics and synbiotics are not the same as probiotics.

Other uses

Probiotics are used in industry to improve yields of pork and chicken production.[82]

Research

Research about probiotics shows benefits.

A study in 2004 testing the immune system of students given either milk or Actimel over a 6 week exam period (3 weeks of studying, 3 weeks of exams) tested 19 different biomarkers. Of these 19 biomarkers only 2 were shown to be different between the two groups, increased production of lymphocytes and increased production of CD56 cells. The tests were not blind and show that certain probiotic strains may have no overall effect on the immune system or on its ability.[83]

A 2007 study at University College Cork in Ireland showed that a diet including milk fermented with Lactobacillus bacteria prevented Salmonella infection in pigs.[84]

A 2007 clinical study at Imperial College London showed that preventive consumption of a commercially available probiotic drink containing L casei DN-114001, L bulgaricus, and S thermophilus can reduce the incidence of antibiotic-associated diarrhea and C difficile-associated diarrhea.[85]

The efficacy and safety of a daily dose of Lactobacillus acidophilus CL1285 in the prevention of AAD was demonstrated by Montreal’s Maisonneuve-Rosemont Hospital, in a clinical study of hospitalized patients.[70]

Current research is focusing on the molecular biology and genomics of Lactobacillus and bifidobacteria. The application of modern whole genome approaches is providing insights into bifidobacterial evolution, while also revealing genetic functions that explain their presence in the particular ecological environment of the gastrointestinal tract.[86]

Criticisms

Some experts are skeptical on the efficacy of many strains and believe not all subjects will benefit from the use of probiotics. A criticism of probiotic supplements is the cost and value of probiotics products.[87]

See also

References

  1. Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria (October 2001). "Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria". Food and Agriculture Organization of the United Nations, World Health Organization. http://www.who.int/entity/foodsafety/publications/fs_management/en/probiotics.pdf. Retrieved 2009-11-04. 
  2. Hamilton-Miller, Professor J. M. T.; G. R. Gibson, W. Bruck. "Some insights into the derivation and early uses of the word ‘probiotic’". British Journal of Nutrition 2003 (90): 845. doi:10.1079/BJN2003954. http://journals.cambridge.org/download.php?file=%2FBJN%2FBJN90_04%2FS0007114503001946a.pdf&code=a5bb6b0c0d0a37101d84a553e6b92ef1. Retrieved 19 November 2009. 
  3. 3.0 3.1 Metchnikoff, E. 1907. Essais optimistes. Paris. The prolongation of life. Optimistic studies. Translated and edited by P. Chalmers Mitchell. London: Heinemann, 1907.
  4. Mach T (November 2006). "Clinical usefulness of probiotics in inflammatory bowel diseases". Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society 57 Suppl 9: 23–33. PMID 17242485. http://www.jpp.krakow.pl/journal/archive/1106_s9/pdf/23_1106_s9_article.pdf. 
  5. Yan F, Polk DB (November 2006). "Probiotics as functional food in the treatment of diarrhea". Current Opinion in Clinical Nutrition and Metabolic Care 9 (6): 717–21. doi:10.1097/01.mco.0000247477.02650.51. PMID 17053425. 
  6. Reid G (September 2008). "Probiotic Lactobacilli for urogenital health in women". J. Clin. Gastroenterol. 42 (Suppl 3 Pt 2): S234–6. doi:10.1097/MCG.0b013e31817f1298. PMID 18685506. 
  7. Vanderhoof JA (November 2008). "Probiotics in allergy management". Journal of Pediatric Gastroenterology and Nutrition 47 Suppl 2: S38–40. doi:10.1097/01.mpg.0000338810.74933.c1. PMID 18931598. 
  8. Vaughan RB (July 1965). "The romantic rationalist: A study of Elie Metchnikoff". Medical History 9: 201–15. PMID 14321564. 
  9. Tissier, H. 1900. Recherchers sur la flora intestinale normale et pathologique du nourisson. Thesis, University of Paris, Paris, France.
  10. Die antagonistische Behandlung chronischer Darmstörungen mit Colibakterien (1918). Med Klin 2: 29–30. 
  11. Cheplin HA, Rettger LF (December 1920). "Studies on the Transformation of the Intestinal Flora, with Special Reference to the Implantation of Bacillus Acidophilus: II. Feeding Experiments on Man". Proceedings of the National Academy of Sciences of the United States of America 6 (12): 704–5. doi:10.1073/pnas.6.12.704. PMID 16576567. 
  12. Rettger, L.F., W.N. Levy, L. Weinstein, and J.E. Weiss. 1935. Lactobacillus acidophilus and its therapeutic application. Yale University Press, New Haven.
  13. Fuller R (May 1989). "Probiotics in man and animals". The Journal of Applied Bacteriology 66 (5): 365–78. PMID 2666378. 
  14. Tannock GW (September 2003). "Probiotics: time for a dose of realism". Current Issues in Intestinal Microbiology 4 (2): 33–42. PMID 14503687. 
  15. Ljungh A, Wadstrom T (editors) (2009). Lactobacillus Molecular Biology: From Genomics to Probiotics. Caister Academic Press. ISBN 978-1-904455-41-7. 
  16. Gilliland SE, Walker DK (April 1990). "Factors to consider when selecting a culture of Lactobacillus acidophilus as a dietary adjunct to produce a hypocholesterolemic effect in humans". Journal of Dairy Science 73 (4): 905–11. doi:10.3168/jds.S0022-0302(90)78747-4. PMID 2111831. http://jds.fass.org/cgi/pmidlookup?view=long&pmid=2111831. 
  17. 17.0 17.1 17.2 17.3 Sanders ME (February 2000). "Considerations for use of probiotic bacteria to modulate human health". The Journal of Nutrition 130 (2S Suppl): 384S–390S. PMID 10721912. http://jn.nutrition.org/cgi/pmidlookup?view=long&pmid=10721912. 
  18. Wollowski I, Rechkemmer G, Pool-Zobel BL (February 2001). "Protective role of probiotics and prebiotics in colon cancer". The American Journal of Clinical Nutrition 73 (2 Suppl): 451S–455S. PMID 11157356. http://www.ajcn.org/cgi/pmidlookup?view=long&pmid=11157356. 
  19. 19.0 19.1 Brady LJ, Gallaher DD, Busta FF (February 2000). "The role of probiotic cultures in the prevention of colon cancer". The Journal of Nutrition 130 (2S Suppl): 410S–414S. PMID 10721916. http://jn.nutrition.org/cgi/pmidlookup?view=long&pmid=10721916. 
  20. 20.0 20.1 20.2 20.3 Reid G, Jass J, Sebulsky MT, McCormick JK (October 2003). "Potential uses of probiotics in clinical practice". Clin. Microbiol. Rev. 16 (4): 658–72. doi:10.1128/CMR.16.4.658-672.2003. PMID 14557292. PMC 207122. http://cmr.asm.org/cgi/pmidlookup?view=long&pmid=14557292. 
  21. 21.0 21.1 Ouwehand AC, Salminen S, Isolauri E (August 2002). "Probiotics: an overview of beneficial effects". Antonie Van Leeuwenhoek 82 (1-4): 279–89. doi:10.1023/A:1020620607611. PMID 12369194. http://www.kluweronline.com/art.pdf?issn=0003-6072&volume=82&page=279. 
  22. Hatakka K, Savilahti E, Pönkä A, et al. (June 2001). "Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial". BMJ 322 (7298): 1327. doi:10.1136/bmj.322.7298.1327. PMID 11387176. 
  23. Näse L, Hatakka K, Savilahti E, et al. (2001). "Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children". Caries Research 35 (6): 412–20. doi:10.1159/000047484. PMID 11799281. 
  24. University of Pennsylvania School of Medicine (February 3, 2010). "'Good' bacteria keep immune system primed to fight future infections". ScienceDaily. http://www.sciencedaily.com/releases/2010/01/100127095945.htm. Retrieved July 13, 2010. 
  25. Hamilton-Miller JM (October 2003). "The role of probiotics in the treatment and prevention of Helicobacter pylori infection". International Journal of Antimicrobial Agents 22 (4): 360–6. doi:10.1016/S0924-8579(03)00153-5. PMID 14522098. 
  26. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ (June 2002). "Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis". BMJ 324 (7350): 1361. doi:10.1136/bmj.324.7350.1361. PMID 12052801. PMC 115209. http://bmj.com/cgi/pmidlookup?view=long&pmid=12052801. 
  27. Cremonini F, Di Caro S, Nista EC, et al. (August 2002). "Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea". Aliment. Pharmacol. Ther. 16 (8): 1461–7. doi:10.1046/j.1365-2036.2002.01318.x. PMID 12182746. 
  28. Mcfarland LV. (2006 Apr). "Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease". Am J Gastroenterol 101 (4): 812–22. doi:10.1111/j.1572-0241.2006.00465.x. PMID 16635227. 
  29. Szajewska H, Mrukowicz J. (2005-09-01). "Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea". Aliment Pharmacol Ther 22 (5): 365–72. doi:10.1111/j.1365-2036.2005.02624.x. PMID 16128673. 
  30. Szajewska H, Ruszczyński M, Radzikowski A. (2006 Sep). "Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials". J Pediatr 149 (3): 367–372. doi:10.1016/j.jpeds.2006.04.053. PMID 16939749. 
  31. 31.0 31.1 Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. (2006 June). "Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials". Lancet Infect Dis 6 (6): 374–82. doi:10.1016/S1473-3099(06)70495-9. PMID 16728323. 
  32. Doron SI, Hibberd PL, Gorbach SL. (2008 Jul). "Probiotics for prevention of antibiotic-associated diarrhea". J Clin Gastroenterol 42 (Suppl 2): S58–63. doi:10.1097/MCG.0b013e3181618ab7. PMID 18542041. 
  33. Surawicz CM. (2008 Jul). "Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea". J Clin Gastroenterol 42 (Suppl 2): S64–70. doi:10.1097/MCG.0b013e3181646d09. PMID 18545161. 
  34. Kirjavainen PV, Salminen SJ, Isolauri E (February 2003). "Probiotic bacteria in the management of atopic disease: underscoring the importance of viability". J. Pediatr. Gastroenterol. Nutr. 36 (2): 223–7. doi:10.1097/00005176-200302000-00012. PMID 12548058. 
  35. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang ML (2008). "Probiotics for treating eczema". Cochrane Database Syst Rev (4): CD006135. doi:10.1002/14651858.CD006135.pub2. PMID 18843705. 
  36. Braat, H; Van Den Brande, J; Van Tol, E; Hommes, D; Peppelenbosch, M; Van Deventer, S (2004). "Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function.". The American journal of clinical nutrition 80 (6): 1618–25. PMID 15585777. 
  37. Famularo G, De Simone C, Pandey V, Sahu AR, Minisola G (2005). "Probiotic lactobacilli: an innovative tool to correct the malabsorption syndrome of vegetarians?". Med. Hypotheses 65 (6): 1132–5. doi:10.1016/j.mehy.2004.09.030. PMID 16095846. 
  38. Hitti, Miranda (April 25, 2006). "Probiotics May Help Stressed Gut". WebMD. http://www.webmd.com/content/article/121/114283.htm. Retrieved 2006-10-24. 
  39. Whorwell PJ, Altringer L, Morel J, et al. (July 2006). "Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome". Am. J. Gastroenterol. 101 (7): 1581–90. doi:10.1111/j.1572-0241.2006.00734.x. PMID 16863564. 
  40. Niedzielin K, Kordecki H, Birkenfeld B (2001). "A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome". Eur J Gastroenterol Hepatol 13 (10): 1143–7. doi:10.1097/00042737-200110000-00004. PMID 11711768. 
  41. Kerr, Martha (May 21, 2003). "Probiotics Significantly Reduce Symptoms of IBS, Ulcerative Colitis". http://www.medscape.com/viewarticle/455964. Retrieved 2006-06-12. 
  42. Guyonnet D, Chassany O, Ducrotte P, et al. (2007). "Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial". Aliment. Pharmacol. Ther. 26 (3): 475–86. doi:10.1111/j.1365-2036.2007.03362.x. PMID 17635382. 
  43. Kruis, W; Fric, P; Pokrotnieks, J; Lukás, M; Fixa, B; Kascák, M; Kamm, MA; Weismueller, J et al. (November, 2004). "Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine". Gut 53 (11): 1617–23. doi:10.1136/gut.2003.037747. PMID 15479682. PMC 1774300. http://www.ncbi.nlm.nih.gov/pubmed/15479682. Retrieved 2010-03-15. 
  44. Reid G (February 2001). "Probiotic agents to protect the urogenital tract against infection". Am. J. Clin. Nutr. 73 (2 Suppl): 437S–443S. PMID 11157354. 
  45. Famularo G, Perluigi M, Pieluigi M, Coccia R, Mastroiacovo P, De Simone C (April 2001). "Microecology, bacterial vaginosis and probiotics: perspectives for bacteriotherapy". Med. Hypotheses 56 (4): 421–30. doi:10.1054/mehy.2000.1195. PMID 11339841. 
  46. Besselink MG, van Santvoort HC, Buskens E, et al. (February 2008). "Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial". Lancet 371 (9613): 651–9. doi:10.1016/S0140-6736(08)60207-X. PMID 18279948. 
  47. 47.0 47.1 Bee, Peta (November 10, 2008). "Probiotics, Not so friendly after all". The Times (London). http://www.timesonline.co.uk/tol/life_and_style/health/features/article5109777.ece. 
  48. "So-called 'friendly' bacteria may be dangerous, according to new research - so which should you be taking?". Daily Mail. 29 January 2008. http://www.dailymail.co.uk/health/article-510978/So-called-friendly-bacteria-dangerous-according-new-research--taking.html. 
  49. "Gut Reactions programme 3". BBC. http://www.bbc.co.uk/radio4/science/gutreactions.shtml. 
  50. Raoult,Didier (September 2009). "Probiotics and obesity : a link ?". Nature 9: 616. doi:10.1038/nrmicro2209. 
  51. Raoult, Didier (2009). "No link between probiotics and obesity? Author reply". Nature Reviews Microbiology 7: 901. doi:10.1038/nrmicro2209-c3. http://www.isapp.net/docs/obesity_and_probiotics_isapp_response_to_raoult.pdf. 
  52. Ehrlich, SD (2009). "Probiotics - little evidence for a link to obesity.". Nature reviews. Microbiology 7 (12): 901; author reply 901. doi:10.1038/nrmicro2209-c1. PMID 19915581. http://www.ncbi.nlm.nih.gov/pubmed/19915581. 
  53. Sanders, ME (June 2007). "Probiotics, strains matter". . Functional foods & nutraceuticals magazine: 36–41. http://www.functionalingredientsmag.com/article/Formulations/probiotics-strains-matter.aspx. 
  54. Hun, Larysa MD, FAAP, L (2009). "Bacillus coagulans Significantly Improved Abdominal Pain and Bloating in Patients with IBS". Postgraduate Medicine 121 (2): 119–124. doi:10.3810/pgm.2009.03.1984. PMID 19332970. http://www.postgradmed.com/index.php?free=pgm_03_2009?article=1984. 
  55. Baron, Mira MD, M (2009). "A patented A Strain of Bacillus coagulans Increased Immune Response to Viral Challenge". Postgraduate Medicine 121 (2): 114–118. doi:10.3810/pgm.2009.03.1971. PMID 19332969. http://www.postgradmed.com/index.php?free=pgm_03_2009?article=1971. 
  56. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS (April 2009). "The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review". The American Journal of Gastroenterology 104 (4): 1033–49; quiz 1050. doi:10.1038/ajg.2009.25. PMID 19277023. 
  57. "About us". Nebraska Cultures. http://nebraskacultures.com/htmls/about_nebraska_cultures.html. Retrieved 2009-02-16. 
  58. Sarker SA, Sultana S, Fuchs GJ, et al. (August 2005). "Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh". Pediatrics 116 (2): e221–8. doi:10.1542/peds.2004-2334. PMID 15995003. 
  59. 59.0 59.1 "Nyttiga bakterier bringar ordning i oroliga sommarmagar" (in Swedish). Norrmejerier. 2003-07-01. http://www.verum.se/default0.asp?varpresentdomain=www.verum.se&varpresenturl=/bib/nm.asp&varpresentqs=Documentkey%3DCA0C5F5F664AC396C1256DC7002BC66F%26DocumentCategoryKey%3DB716C33872CE35C5C1256DBF003D3EB9&redir=1. Retrieved 2007-08-25. 
  60. Ruiz-Palacios G, Guerrero ML, Hilty M. (1996). "Feeding of a probiotic for the prevention of community-acquired diarrhea in young Mexican children.". Pediatr Res 39 (4): 184. http://www.noosit.com/02Prodotti/01reuterin/approfondimenti/02documenti/05-Feeding_of_a_probiotic_for_the_prevention_of_community.pdf. 
  61. Shornikova AV, Casas IA, Mykkänen H, Salo E, Vesikari T (December 1997). "Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis". Pediatr. Infect. Dis. J. 16 (12): 1103–7. doi:10.1097/00006454-199712000-00002. PMID 9427453. 
  62. Saggioro A, Caroli M, Pasini M, Bortoluzzi F, Girardi L, Pilone G. (2005). "Helicobacter pylori eradication with Lactobacillus reuteri. A double blind placebo-controlled study.". Dig Liver Dis 37 (suppl 1): S88, abstr. PO1.49. 
  63. Krasse P, Carlsson B, Dahl C, Paulsson A, Nilsson A, Sinkiewicz G (2006). "Decreased gum bleeding and reduced gingivitis by the probiotic Lactobacillus reuteri". Swed Dent J 30 (2): 55–60. PMID 16878680. 
  64. Weizman Z, Asli G, Alsheikh A (January 2005). "Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents". Pediatrics 115 (1): 5–9. doi:10.1542/peds.2004-1815 (inactive 2009-08-03). PMID 15629974. 
  65. Tubelius P, Stan V, Zachrisson A (2005). "Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised, double-blind placebo-controlled study". Environ Health 4: 25. doi:10.1186/1476-069X-4-25. PMID 16274475. 
  66. Hochter, W. et al.. "Saccharomyces boulardii in acute adult diarrhea. Efficacy and tolerance of treatment" (PDF). Munchener Medizinische Wochenschrift 132 (12): 188–192. http://www.dtecta.co.uk/casestudies/Hochter_(1990)_Saccharomyces_boulardii_in_acute_adult_diarrhoea_Efficacy_and_tolerance_of_treatment_DiarSafe_DTECTA_Probiotics_www.dtecta.co.uk.pdf. 
  67. Cetina-Sauri, G. & Basto, S.. "Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea" (PDF). Annales de Pediatrie 41 (6): 397–400. http://www.dtecta.co.uk/casestudies/Cetina_Sauri_&_Basto_(1994)_Therapeutic_Evaluation_of_Saccharomyces_boulardii_in_children_with_acute_diarrhoea_DiarSafe_DTECTA_Probiotics_www.dtecta.co.uk.pdf. 
  68. Kurugöl Z, Koturoğlu G (January 2005). "Effects of Saccharomyces boulardii in children with acute diarrhoea". Acta Paediatrica 94 (1): 44–7. doi:10.1080/08035250410022521. PMID 15858959. 
  69. Anukam K, Osazuwa E, Ahonkhai I, et al. (May 2006). "Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial". Microbes Infect. 8 (6): 1450–4. doi:10.1016/j.micinf.2006.01.003. PMID 16697231. 
  70. 70.0 70.1 Beausoleil M, Fortier N, Guénette S, et al. (November 2007). "Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial". Canadian Journal of Gastroenterology 21 (11): 732–6. PMID 18026577. PMC 2658588. http://www.pulsus.com/journals/abstract.jsp?sCurrPg=journal&jnlKy=2&atlKy=7643&isuKy=749&isArt=t. 
  71. Millette, M; Luquet, FM; Lacroix, M (March 2007). ""In vitro growth control of selected pathogens by Lactobacillus acidophilus- and Lactobacillus casei-fermented milk". Letters of Applied Microbiology 44 (3): 314–9. doi:10.1111/j.1472-765X.2006.02060.x. PMID 17309510. 
  72. Robinson, R.K., ed (2007). "Sellars, R.L.". "Acidophilus Products (Therapeutic Properties of Fermented Milks)". Chapman & Hall, London. pp. 81–116. 
  73. Seseña, S; Palop, ML; M.Ll. Palop (2007). "An ecological study of lactic acid bacteria from Almagro eggplant fermentation brines". Journal of Applied Microbiology (Blackwell Publishing) 103 (5): 1553–1561. doi:10.1111/j.1365-2672.2007.03387.x. PMID 17953566. http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2672.2007.03387.x. Retrieved 7 November 2007. 
  74. 74.0 74.1 Breidt, Jr, Frederick et al. (2007). "Fermented Vegetables" (PDF). ASM Press. http://fsweb2.schaub.ncsu.edu/USDAars/Acrobatpubs/P329-350/P345.pdf. Retrieved 7 November 2007. 
  75. Ji, Feng-Di et al.; Ji, B.-P.; Li, B.; Han, B.-Z. (2007). "Note. Microbial Changes During the Salting Process of Traditional Pickled Chinese Cabbage". Food Science and Technology International (SAGE Publications) 13 (1): 11–16. doi:10.1177/1082013207075952. http://fst.sagepub.com/cgi/content/abstract/13/1/11. Retrieved 7 November 2007. 
  76. Moreno, M.R.F. et al.; Leisner, JJ; Tee, LK; Ley, C; Radu, S; Rusul, G; Vancanneyt, M; De Vuyst, L (2002). "Microbial analysis of Malaysian tempeh, and characterization of two bacteriocins produced by isolates of Enterococcus faecium". Journal of Applied Microbiology (The Microbiology Research Foundation) 92 (1): 147–157. doi:10.1046/j.1365-2672.2002.01509.x. PMID 11849339. http://www.blackwell-synergy.com/doi/abs/10.1046/j.1365-2672.2002.01509.x. Retrieved 7 November 2007. 
  77. Oh, CK; Oh, MC; Kim, SH (2004). "The Depletion of Sodium Nitrite by Lactic Acid Bacteria Isolated from Kimchi". Journal of Medicinal Food (Mary Ann Liebert) 7 (1): 38–44. doi:10.1089/109662004322984680. PMID 15117551. http://www.liebertonline.com/doi/abs/10.1089/109662004322984680?cookieSet=1&journalCode=jmf. Retrieved 7 November 2007. 
  78. Sybesma, Y; Hugenholtz, Jeroen; De Vos, Willem M.; Smid, Eddy J. (2006). "Safe use of genetically modified lactic acid bacteria in food. Bridging the gap between consumers, green groups, and industry". Electronic Journal of Biotechnology (Pontificia Universidad Católica de Valparaíso) 9 (4): 0. doi:10.2225/vol9-issue4-fulltext-12. PMID 16710463. PMC 1463031. http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-34582006000400011&tlng=&lng=en&nrm=iso. Retrieved 7 November 2007. 
  79. Tanasupawat, Somboon et al.; Thongsanit, J; Okada, S; Komagata, K (2002). "Lactic acid bacteria isolated from soy sauce mash in Thailand". Journal of General and Applied Microbiology (The Microbiology Research Foundation) 48 (4): 201–209. doi:10.2323/jgam.48.201. PMID 12469319. http://www.jstage.jst.go.jp/article/jgam/48/4/201/_pdf. Retrieved 6 November 2007. 
  80. Timmerman HM, Koning CJ, Mulder L, Rombouts FM, Beynen AC (November 2004). "Monostrain, multistrain and multispecies probiotics—A comparison of functionality and efficacy". Int. J. Food Microbiol. 96 (3): 219–33. doi:10.1016/j.ijfoodmicro.2004.05.012. PMID 15454313. 
  81. Williams E, Stimpson J, Wang D, et al. (September 2008). "Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study". Aliment. Pharmacol. Ther. 29: 97. doi:10.1111/j.1365-2036.2008.03848.x. PMID 18785988. 
  82. Les yaourts font-ils grossir?
  83. [1]
  84. Probiotics may protect against food poisoning
  85. Hickson M, D'Souza AL, Muthu N, et al. (2007). "Use of probiotic Lactobacillus preparation to prevent diarrhea associated with antibiotics: randomised double blind placebo controlled trial". BMJ 335 (7610): 80. doi:10.1136/bmj.39231.599815.55. PMID 17604300. 
  86. Mayo, B; van Sinderen, D (editor) (2010). Bifidobacteria: Genomics and Molecular Aspects. Caister Academic Press. ISBN 978-1-904455-68-4. 
  87. Bee, Peta (November 10, 2008). "Probiotics, not so friendly after all?". The Times (London). http://www.timesonline.co.uk/tol/life_and_style/health/features/article5109777.ece. Retrieved 18 June 2010. 

External links